Clinical trial
Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169026 · Dartmouth-Hitchcock Medical Center, Other · Terminated
Key facts
| NCT number | NCT00169026 |
|---|---|
| Title | Alcoholism and Schizophrenia: Effects of Clozapine |
| Official title | Alcoholism and Schizophrenia: Effects of Clozapine |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIH Harvard Medical School (HMS and HSDM) Commonwealth Research Center, Massachusetts Novartis Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse |
| Intervention type | Drug |
| Interventions | Clozapine versus typical (conventional) and atypical antipsychotic medications |
| Enrollment | 64 |
| Start date | May 1, 1999 |
| Completion | Jan 1, 2004 |
| First posted | Sep 15, 2005 |
| Last update posted | Mar 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: